Search Immortality Topics:

Page 12«..11121314..2030..»


Impact of COVID-19 on Biochemical Oxygen Demand Market Latest trending report is booming globally by Top Leading Players LAR, Hach, Lovibond, VELP,…

Posted: August 12, 2020 at 1:54 pm

Note: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Biochemical Oxygen DemandMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Biochemical Oxygen Demand Market Players to battle Covid-19 Impact.

The Biochemical Oxygen DemandMarket report is compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in future. It offers detailed research and analysis of key aspects of the Biochemical Oxygen Demand market. Readers will be able to gain deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the global Biochemical Oxygen Demand market. Buyers of the report will have access to accurate PESTLE, SWOT and other types of analysis on the global Biochemical Oxygen Demand market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Biochemical Oxygen Demand markets to extend their reach and create sales opportunities.

The study encompasses profiles of major Companies/Manufacturers operating in the global Biochemical Oxygen Demand Market.Key players profiled in the report include:LAR, Hach, Lovibond, VELP, YSI (Xylem), Skalar, Mantech-Inc, Mettler Toledo, Thermo Fisher Scientific, WTW (Xylem), Camlab, Ohkura and More

Get PDF Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/143683

Segmental Analysis:The report has classified the global Biochemical Oxygen Demand market into segments including product type and application. Every segment is evaluated based on share and growth rate. Besides, the analysts have studied the potential regions that may prove rewarding for the Biochemical Oxygen Demand manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, there by helping market players to gain deep insights into the overall Biochemical Oxygen Demand industry.

Market Segment By Type:Laboratory BOD AnalyzerPortable BOD AnalyzerOnline BOD Analyzer

Market Segment By Application:Municipal Wastewater Treatment PlantsIndustrial Production FacilitiesLaboratoriesOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/143683

The authors of the report have analyzed both developing and developed regions considered for the research and analysis of the global Biochemical Oxygen Demand market. The regional analysis section of the report provides an extensive research study on different regional and country-wise Biochemical Oxygen Demand industry to help players plan effective expansion strategies.

Regions Covered in the Global Biochemical Oxygen Demand Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

For More Information:https://www.marketinforeports.com/Market-Reports/143683/Biochemical-Oxygen-Demand-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/143683/Biochemical-Oxygen-Demand-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]Website: http://www.marketinforeports.com

View original post here:
Impact of COVID-19 on Biochemical Oxygen Demand Market Latest trending report is booming globally by Top Leading Players LAR, Hach, Lovibond, VELP,...

Recommendation and review posted by G. Smith

Governor Cooper Announces Genetic Medicine Company Will Create 201 Jobs in Durham County – NC Dept of Commerce

Posted: August 12, 2020 at 1:52 pm

Governor Roy Cooper announced today that Beam Therapeutics (Nasdaq; BEAM), a biotechnology company developing precision medicines through DNA base editing, plans to build a manufacturing facility in North Carolinas Research Triangle Park, creating 201 jobs. Over a period of 5 years, the company expects to invest $83 million in the facility, which will support clinical and commercial manufacturing for the companys novel base editing programs.

"North Carolina is a leader in biotechnology, from the research in our labs to the states biomanufacturers, said Governor Cooper. Companies like Beam Therapeutics work in developing precision medicines will help keep North Carolina on the cutting edge of this industry.

Beam Therapeutics, with headquarters in Cambridge, Massachusetts, develops precision genetic medicines through base editing. The foundational level of genetic information is a single base letter in DNA, and an error to a single letter, known as a point mutation, can cause disease. Base editors have the ability to rewrite just a single letter, and thereby intervene at the most foundational level. Beams proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.

We believe investment in strategic manufacturing capabilities is an important component of fully realizing the power of our base editing technology and achieving our vision to provide life-long cures to patients suffering from serious diseases, said John Evans, CEO of Beam Therapeutics. Research Triangle Park is a thriving biopharmaceutical hub, providing significant access to the broad range of talent we will need to make this vision a reality.

Although wages will vary depending on position, the average salary for the new positions will be $102,654. The average wage in Durham County is $71,756. The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll.

"North Carolina has been a world leader in biotechnology for many years, but were not resting on our past accomplishments, said North Carolina Commerce Secretary Anthony M. Copeland. Beam Therapeutics joins a host of gene therapy companies that are keeping North Carolina at the forefront of this new frontier of medicine.

Beam Therapeutics project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the states Economic Investment Committee earlier today. Over the course of 12 years, the project is estimated to grow the states economy by $1.36 billion. Using a formula that takes into account the new tax revenues generated by the new jobs, the agreement authorizes the potential reimbursement to the company of up to $3,237,750, spread over 12 years. Payments for all JDIGs only occur following performance verification by the departments of Commerce and Revenue that the company has met its incremental job creation and investment targets. JDIG projects result in positive net tax revenue to the state treasury, even after taking into consideration the grants reimbursement payments to a given company.

Because Beam Therapeutics chose a site in Durham County, classified by the states economic tier system as Tier 3, the companys JDIG agreement also calls for moving as much as $1,079,250 into the states Industrial Development Fund Utility Account. The Utility Account helps rural communities finance necessary infrastructure upgrades to attract future business. Even when new jobs are created in a Tier 3 county such as Durham, the new tax revenue generated through JDIG grants helps more economically challenged communities elsewhere in the state. More information on the states economic tier designations is available here.

In addition to the North Carolina Department of Commerce and the Economic Development Partnership of N.C., other key partners on this project were the the North Carolina Community College System, the North Carolina Biotechnology Center, Durham County, and the Greater Durham Chamber of Commerce.

View original post here:
Governor Cooper Announces Genetic Medicine Company Will Create 201 Jobs in Durham County - NC Dept of Commerce

Recommendation and review posted by G. Smith

Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic…

Posted: August 12, 2020 at 1:52 pm

CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. Through the agreement, Sarepta will fund multiple research programs at the University, and will have an exclusive option to further develop any new therapeutic compounds that result from the funded research programs.

We have developed a productive incubator approach to our pipeline development, partnering with the best and brightest in genetic medicine, including leading academic researchers like those at the University of Florida, to discover and translate into meaningful therapies genetic medicine for rare diseases, said Sarepta President and CEO Doug Ingram. Weare excited topartner with andsupportUF research that has the potentialto profoundlyimproveand extend the lives of patients with rare genetic-based diseases.

Through the collaboration, currently unique to UF, funding has been allocated for four innovative projects. These projects include exploratory research in novel gene therapy vectors, next-generation capsids and gene editing technologies as well as work in new therapeutic areas in degenerative genetic diseases. The goal is to foster early relationships with experts and accelerate the scientific advancements that lead to the development of transformational precision genetic medicines for patients in need.

Our researchers intend to find solutions for diseases that have no cure or limited therapeutic options. Their goal is to move these solutions from their labs to patients who need them to see their discoveries change lives. Because Sarepta has a focus and expertise in disease areas that coincide with the work of some of our scientists, its a match and collaboration that make sense and, we hope, will save lives, said Jim OConnell, assistant vice president of UF Innovate, the technology commercialization arm of the university. Sarepta has a bold vision for transforming genetic disease because the company, ultimately, serves patients. That end goal drives its willingness and ability to translate research into a medical reality. We want to be part of that.

University of Florida is a gene therapy powerhouse. UF researchers were the first to discover the life cycle of the adeno-associated virus (AAV), the smallest human virus. Using AAV as a benign delivery vehicle to carry therapeutics to a target, UF was first to reverse blindness in dogs with genetic disease, and UF researchers were integral in the first gene therapy approved by the FDA to treat an inherited genetic disease that can cause blindness. Today, UF is developing technologies in manufacturing, capsid design and therapies to address neuromuscular, cardiovascular, inflammatory, metabolic, pulmonary, skeletal, ophthalmic, and other disorders.

About SareptaAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.comor follow us onTwitter,LinkedIn,InstagramandFacebook.

Sarepta Forward-Looking Statements This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the ability of the collaboration between Sarepta and UF to engage in cutting-edge research for novel genetic medicines; Sareptas commitment to fund multiple research programs at UF; Sareptas option to further develop any new therapeutic compounds that result from the funded research programs; Sareptas incubator approach to discover and translate into meaningful therapies genetic medicine for rare diseases; the collaborations potential to profoundly improve and extend the lives of patients with rare genetic-based diseases; the collaborations ability to foster early relationships with experts to accelerate the scientific advancements that lead to the development of transformational precision genetic medicines; and Sareptas vision to transform genetic disease and translate research into a medical reality.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: the expected benefits and opportunities related to the collaboration between Sarepta and UF may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development. In particular, the collaboration may not result in the discovery of any new therapeutic compounds or any viable treatments suitable for commercialization due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates and the COVID-19 pandemic; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sareptas business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Contacts:

Sarepta Therapeutics Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.comMedia: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

UF Innovate: Sara Dagen, 352-294-0998, saradagen@ufl.edu

See original here:
Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic...

Recommendation and review posted by G. Smith

5 things to know about CRISPR and gene editing in the COVID era – World Economic Forum

Posted: August 12, 2020 at 1:52 pm

One of the most common misconceptions about CRISPR is that its only useful for gene editing. In reality, CRISPR can be used for a wide variety of non-gene editing applications, ranging from diagnostics to antiviral applications.

There is also a perception that the gene-editing mechanism of CRISPR is the bottleneck for curing all disease. The reality is that, for many applications, the bottleneck is actually our understanding of the genetic code itself or the limitations of what changing that code can actually accomplish. How factors interplay with our genetic code to produce diseases is a field that is critical for unlocking gene editings full potential.

One of the most perplexing aspects of COVID-19 is its enormous range of symptoms. Three people might contract it and have no overlap in their experience. Precision medicine an innovative approach to care that takes into account an individuals genes, environment, and lifestyle is playing a key role in understanding the genetic and environmental factors that might explain why one person is asymptomatic while another must be put on a ventilator, says Cameron Fox, Specialist on Precision Medicine at the World Economic Forum, and an expert in COVID-19 diagnostics technology.

Beyond the current crisis, this innovative work will have lasting, positive effects on many facets of the health ecosystem. One example is CRISPR-based diagnostics. CRISPRs ability to rapidly and accurately diagnose a wide range of diseases is only now being seriously explored. If this technology can be perfected, it would be a gamechanger in our fight against COVID-19, Fox continues.

Mammoth Biosciences is a World Economic Forum Global Innovator at the forefront of these developments. Here are five things Mammoths Co-Founder and CEO Trevor Martin thinks are important to know about how the field is evolving in the era of COVID-19.

The advent of CRISPR-based diagnostics fundamentally means a better understanding of the molecular world around us for areas ranging from human disease to crop health.

Infectious disease is a key use-case area for the diagnostic applications of CRISPR. Its become clear that one of its most powerful uses is its ability to provide reliable molecular information quickly and in a variety of formats.

International borders, workplaces, homes and maybe even concerts, conferences or other large events could benefit greatly from having tests for COVID-19 (and other diseases) that give gold-standard results within minutes. During a pandemic, this type of information is critical for fully reopening economies and engaging in robust contact tracing.

We created a robust test for the novel coronavirus within weeks particularly important as we contemplate the fact that it is a matter of when, not if, we must combat future pandemics beyond the current one, says Trevor Martin.

Beyond these more immediate uses, there is exciting potential for testing our environment more broadly, through monitoring samples from sewage or air. These measurements could give us unprecedented insight into our ecosystems and how they influence our health.

As CRISPR-based diagnostics pave the way for decentralized testing, the technological disruption will also open the door for accelerated adoption of value-based care models, rather than fee-for-service healthcare as in the United States.

Decentralized testing allows people to have more control over their own health and understand better when and how to interact with the healthcare system. Ideally, robust and prevalent diagnostics could mean fewer physical visits to a doctor (and shorter wait times), but the same or higher quality of care for more people by supercharging a doctors ability to care for patients through virtual consultations.

To reach its full potential, decentralized testing needs to go beyond its current model of expensive and complicated boxes with cartridges and embrace fully democratizable formats that can be used by individuals without extensive training. For example, Mammoth is creating CRISPR-based tests for diseases like COVID-19 in a format similar to a pregnancy test. This truly decentralized testing will allow for greater access to care and better information about when to seek it.

The application of precision medicine to save and improve lives relies on good-quality, easily-accessible data on everything from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast, untapped potential to transform the treatment and prediction of rare diseasesand disease in general.

But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.

The World Economic Forums Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access across borders to sensitive health data for the treatment and diagnosis of rare diseases.

The data will be shared via a federated data system: a decentralized approach that allows different institutions to access each others data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.

The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare).

COVID-19 has opened many peoples eyes to the massive and surprising gaps in infectious disease diagnostics.

Diagnostics is, currently, a space where you must choose between a highly accurate result that requires long turn-around times and trained personnel and/or expensive equipment or a rapid result in an accessible format that sacrifices sensitivity and specificity.

COVID-19 has also made us more conscious of our shared responsibility to combat these unique types of diseases that we silently spread to each other. Hopefully, through focused investment in technology development as well as an elevated societal and government focus on detecting, curing and preventing infectious diseases, we can not only fight this pandemic but come out stronger against emerging infectious diseases.

The adage an ounce of prevention is worth a pound of cure will be more relevant than ever as weve seen the devastating effects and herculean efforts required to control and cure an infectious disease once it has evaded containment and prevention techniques.

As part of the focus on prevention, we need to ensure that as many people as possible have access to and entry points into broader healthcare networks. Access in particular should become a key focus as this pandemic has highlighted that we are only as strong as the most vulnerable among us. This challenges the current model of service-based healthcare.

Furthermore, biotechnology will become a top strategic priority for many governments, as an ability to prevent and mitigate a pandemic is an enormous political and economic advantage. It will become ever more important to understand and focus on how to communicate sound science broadly and in a way that all people trust. Weve seen in this pandemic that the increased use of pre-print servers has accelerated an amazing new model for rapidly disseminating cutting-edge science so people around the world can collaborate and build on it quickly. At the same time, it is harder than ever for individuals to know what is relevant and real. It will be important to find ways to retain the shift in pace, speed and openness of communication while maintaining the reliability and trust that gatekeeping mechanisms like peer-reviewed journals have long tried to provide.

Reliable, accurate and understandable information is key for both. We need consensus sources of information that are trusted by diverse groups and backed by strong science internationally.

People want what is best for their communities, their families and themselves, but it can be hard to separate fact from fiction. It is all the more important to ensure we have robust and frequent communication about science as well as forums that allow for stakeholders of all stripes to participate in a conversation on their benefits and drawbacks.

Ethical use of these technologies should not and cannot be determined only by a single group or individual. It is a shared responsibility across patients, industry, government and civic leaders. Understanding the molecular world and modifying it are increasingly tractable and accessible notions, but the use and misuse of technologies like CRISPR are important topics that have no easy answers.

The bottom line: It is critical that the public has an opportunity to understand how these technologies work and access to informed and rigorous sources of information for doing so, concludes Trevor Martin. Equally important, we must make sure that this information and insight is distributed widely and equally so that all of us participate in shaping and can benefit from these exciting advances.

Image: World Economic Forum

Last year, the World Economic Forum launched Strategic Intelligence, its flagship digital product to help individuals and organizations see the big picture on the global issues facing the world. It provides a tremendous resource for exploring the interconnections between over 250 different topics and keeping up to date on everything that could potentially be an opportunity or a risk to you or your organization. Strategic Intelligence enables organizations, like the Global Innovators, to keep abreast of risks, opportunities and trends, enabling them to take more of a data-driven approach to managing their business.

Read more:
5 things to know about CRISPR and gene editing in the COVID era - World Economic Forum

Recommendation and review posted by G. Smith

In the face of COVID-19, cell and gene therapy space shows ‘remarkable resilience:’ report – FierceBiotech

Posted: August 12, 2020 at 1:52 pm

In the early days of COVID-19, the Alliance for Regenerative Medicine (ARM) was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space.

It was a really specific time when the world and the markets were clearly reeling from the first appreciation for the seriousness of COVID-19, Janet Lambert, the organizations CEO said.

Now, the numbers are inand theyre better than ever. In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total capital raised in 2019 and a 120% jump over the first half of 2019, ARM found in a new report titled, Innovation in the Time of COVID-19. The proceeds were shared pretty evenly between cell therapy companies ($7.5 billion) and gene and gene-modified cell therapy companies ($7.9 billion), with companies focused on tissue engineering reeling in $84 million.

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

RELATED: Biotech IPO bonanza: Legend's $350M offering as Repare, Forma get in on the action

That $10.7 billion was driven by a couple of outsize deals and includes $1.4 billion raised in five IPOs, $1.6 billion in follow-on offerings and $3 billion in venture capital. Chinese CAR-T player Legend Biotech led the pack with its mammoth $487 million Wall Street debut in June, but its peers netted considerable sums too. That same month, gene therapy companies Generation Bio and Akouos raised $230 million and $244 million, respectively. In February, another gene therapy outfit, Passage Bio, raised $284 million and gene-editing biotech Beam Therapeutics bagged $207 million.

On the venture side, Sana Biotechnology scored $700 millionalmost as much as the five next largest private rounds raised by Orca Bio Elevate Bio, Legend, Freeline Therapeutics and Poseida, the report found. Like Legend, Generation Bio and Akouos also completed sizable private rounds the same year they went public.

RELATED: 'The silver lining': Biotech IPOs in the time of coronavirus

All this enthusiasm for this sector right now is evidenced by these really astonishing financing numbers I think the drivers of that enthusiasm remain in place and make me optimistic for the second half of 2020, Lambert said. We continue to see really promising clinical results. We continue to see products making it to market. We continue to see patient, regulator and payer enthusiasm for these products.

Part of that enthusiasm stems from an appreciation for the biotech sector generally, Lambert said.

Attention is being paid to what the biopharma sector can do for us all as we try to weather and get out of the pandemic, she said, echoing the sentiments of venture capitalists whove managed to raise life sciences funds in spite of the pandemic.

The other side of the equation is the nature of biotechbecause the drug development cycle is long, biotech investors arent looking for quarter-to-quarter returns, but at milestone readouts that can come more than a year after IPO, Jordan Saxe, head of healthcare listings at Nasdaq, said in a previous interview.

Biotech is actually fairly well positioned to weather these kinds of events because youre not relying on day-to-day consumer spending. Youre relying on meaningful clinical catalysts at the end of the day to really generate value, and thats still going to be there in this environment, said Jason Pitts, Ph.D., a principal at Sofinnova, in ARMs report.

RELATED: Flagship raises $1.1B to create biotechs for post-pandemic world

All this gas in the tank isnt just bankrolling existing cell and gene therapies, but also driving company formation, Lambert said. For the first time, ARM counts more than 1,000 companies working in the sector, with more than 1,000 clinical trials going on worldwide. More than half of those studies are in phase 2, with just over a third in phase 1 and the remainder in phase 3.

Of those studies, 11 are testing regenerative medicine approaches against COVID-19, with several academic research centers and biopharma companies working on new treatments to treat the disease in the short and long term.

Most of them are using cell therapies to address ARDS, or acute respiratory distress syndrome, which is a consequence of COVID-19, Lambert said. Unlike other prospects in the pipeline, such as antibodies, which could potentially be used to prevent infection as well as treat it, regenerative treatments focus on repairing damage to the lungs or other organs that patients can suffer as part of COVID-19.

More:
In the face of COVID-19, cell and gene therapy space shows 'remarkable resilience:' report - FierceBiotech

Recommendation and review posted by G. Smith

Global Gene Synthesis Market Will Reach USD 27308 Million By 2027: Facts and Factors – PharmiWeb.com

Posted: August 12, 2020 at 1:52 pm

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

See the original post:
Global Gene Synthesis Market Will Reach USD 27308 Million By 2027: Facts and Factors - PharmiWeb.com

Recommendation and review posted by G. Smith


Page 12«..11121314..2030..»